Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use MOTPOLY XR safely and effectively. See full prescribing information for MOTPOLY XR. MOTPOLY XR(lacosamide)™ extended-release capsules, for oral use, CV Initial U.S. Approval: 2008
Medication labelWhy this: Advisory · dailymed-prescription
MOTPOLY XR is indicated for the treatment of partial-onset seizures in adults and in pediatric patients weighing at least 50 kg. MOTPOLY XR is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and in pediatric patients weighing at least 50 kg. Additional pediatric use information is approved for UCB Inc.'s Vimpat (lacosamide) tablets, oral solution, and intravenous solution. However, due to UCB Inc.'s marketing exclusivity rights, this drug product is not labeled with that pediatric information.
- generic_name
- lacosamide
- product_names
- lacosamide
- ndc
- 73289-0063, 73289-0063-2, 73289-0063-1, 73289-0064, 73289-0064-2, 73289-0065, 73289-0065-2
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en